Inflammatory Bowel Disease

Patients with inflammatory bowel disease treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results.

Higher cumulative exposure to systemic antibiotic therapy may be associated with higher risk for the development of inflammatory bowel disease, according to research published in Lancet Gastroenterology & Hepatology.

Dilating small intestinal Crohn’s disease strictures with balloon-assisted enteroscopy had good short-term technical and clinical efficacy, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.

Achieving endoscopic remission may be difficult for patients with Crohn’s disease with larger and deep ulcers in the ileum or rectum, according to results published in the American Journal of Gastroenterology.

Patients with inflammatory bowel disease discontinued methotrexate therapy at twice the rate seen in those who used optimized thiopurine therapy, according to study results.

Etrolizumab, an investigational drug developed by Genentech, failed to meet the primary maintenance endpoints in several phase 3 trials and had mixed results in other induction studies, according to a company press release.

Current or past smoking was not associated with increased risk for the development of pouchitis in patients with ulcerative colitis, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.

After 52 weeks of treatment, Stelara helped induce clinical and endoscopic remission in patients with refractory Crohn’s disease, according to study results.

Here we present some of our most recent reports on their work, as well as some insight from practicing GIs on how the pandemic has impacted daily life and practice.

Investigators found vancomycin preconditioning followed by SER-287 was significantly more effective compared with placebo for induction of remission in patients with active mild-to-moderate ulcerative colitis.